Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
viagenpumatucel-L (HS-110)
i
Other names:
HS-110, HS110 vaccine, HS-L1 therapeutic vaccine
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Scorpius Holdings
Drug class:
Endoplasmin modulator, Endoplasmin stimulant
‹
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
TMB-L
Non Small Cell Lung Cancer
TMB-L
Non Small Cell Lung Cancer
nivolumab + HS-110
Sensitive: C3 – Early Trials
nivolumab + HS-110
Sensitive
:
C3
nivolumab + HS-110
Sensitive: C3 – Early Trials
nivolumab + HS-110
Sensitive
:
C3
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + HS-110
Sensitive: C3 – Early Trials
nivolumab + HS-110
Sensitive
:
C3
nivolumab + HS-110
Sensitive: C3 – Early Trials
nivolumab + HS-110
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login